[Objective] The paper presents the pharmacokinetics of Junmie in healthy rabbits and thus provides a basis for its rational application. [ Method] HPLC method was developed to detect the concentration of Junmie with b...[Objective] The paper presents the pharmacokinetics of Junmie in healthy rabbits and thus provides a basis for its rational application. [ Method] HPLC method was developed to detect the concentration of Junmie with benzoyl ciprofloxacin as internal standard. After the healthy rab bits was respectively injected Junmie intravenously and intramuscularly, plasma concentration after injection was detected with the established HPLC method so as to determine the best pharmacokinetic model. [Result] The conditions of HPLC were as follows： mobile phase was 100 ml 60% （V/V） methanol solution （pH 3.0） ; flow rate was 1.0 mVmin; column temperature was （25.0 ±0.5） ℃; detection wavelength was 278 nm. The concentration time data of the plasma, collected from intravenously and intramuscularly injected rabbits, was separately in line with the two com partments and one compartment open model with the first order absorption. The main pharmacokinetic parameters of the plasma sample （ i. v. ） were as below： T1/2= = 0.07 h, T1/2 = 0.82 h, AUC = 3.51 mg/（L . h）, CLB = 4.57 L/（kg . h） ; the plasma sample （i. m. ） ： T1/2 = 0.33 h, T1/2k = 0.33 h, Tp = 0.6 h, Cmax = 2.55 μg/ml, AUC = 4.87 mg/（L . h）. The bioavailability was approximately 110%. [Conclusion] After intra muscular administration, Junmie is absorbed and eliminated quickly with high bioavallability and extensive distribution.展开更多
文摘[Objective] The paper presents the pharmacokinetics of Junmie in healthy rabbits and thus provides a basis for its rational application. [ Method] HPLC method was developed to detect the concentration of Junmie with benzoyl ciprofloxacin as internal standard. After the healthy rab bits was respectively injected Junmie intravenously and intramuscularly, plasma concentration after injection was detected with the established HPLC method so as to determine the best pharmacokinetic model. [Result] The conditions of HPLC were as follows： mobile phase was 100 ml 60% （V/V） methanol solution （pH 3.0） ; flow rate was 1.0 mVmin; column temperature was （25.0 ±0.5） ℃; detection wavelength was 278 nm. The concentration time data of the plasma, collected from intravenously and intramuscularly injected rabbits, was separately in line with the two com partments and one compartment open model with the first order absorption. The main pharmacokinetic parameters of the plasma sample （ i. v. ） were as below： T1/2= = 0.07 h, T1/2 = 0.82 h, AUC = 3.51 mg/（L . h）, CLB = 4.57 L/（kg . h） ; the plasma sample （i. m. ） ： T1/2 = 0.33 h, T1/2k = 0.33 h, Tp = 0.6 h, Cmax = 2.55 μg/ml, AUC = 4.87 mg/（L . h）. The bioavailability was approximately 110%. [Conclusion] After intra muscular administration, Junmie is absorbed and eliminated quickly with high bioavallability and extensive distribution.
